medigraphic.com
Academia Mexicana de Neurología, A.C.

2005, Number 4

<< Back Next >>

Rev Mex Neuroci 2005; 6 (4)

Personality and addictions

Souza y Machorro M

Language: Spanish
References: 87
Page: 336-345
PDF size: 89.21 Kb.


ABSTRACT

The present paper describes a review of the scientific literature intentionally guided and realized to present the current state of a group of the most important studied biological, psychological and social aspects and correlated with the functioning of the personality, about its interaction in the production and maintenance of the problem solving of the excessive psychotropics’ consumption and addiction. Besides, and to the effect of being correlated across this brief vision, some of the current guidelines of the available antiaddictive therapeutics in the country are stated, and always observed from the optics of the professional programs, they allow to place the clinical accent on the psychotherapeutic work as fundamental complement of the handling and the humanistic essential treatment that the patients must receive in this and all the areas of human pathology, with a view to consolidating in the members of the health staff, the integral vision of the handling of patients with problems of psychotropic abuse/addiction, his comorbidity and complications.


REFERENCES

  1. Souza y MM. Diagnóstico y tratamiento de los síndromes adictivos. México: Ciencia y Cultura Latinoamérica; 2000.

  2. Souza y MM. Consideraciones y fundamentos para una terapéutica profesional de las adicciones. Rev Mex Neuroci 2003; 4(5): 326-30.

  3. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001; 344: 1594-602.

  4. Lasagna L. The powerful placebo: from ancient priest to modern physician. N Engl J Med 1998; 338: 1236-7.

  5. Camí J, Farré M. Mechanisms of disease: drug addiction. N Engl J Med 2003; 349: 975-86.

  6. Souza y MM. Modelos profesionales de tratamiento. Fundación de investigaciones sociales, A.C. Modelos de tratamiento para el alcoholismo. Cuadernos FISAC; 2004: 25-46.

  7. Guisa CVM, Díaz Barriga SL, Souza y MM. Terapéutica antiadictiva: utilidad de sus factores de predicción. México: Dirección de Tratamiento. Centros de Integración Juvenil, A.C.; 2004.

  8. Hirschfeld RMA. Of two minds: the revolutionary science of dual-brain psychology. N Engl J Med 1999; 340: 1218-9.

  9. Souza y MM, Quijano BEM, Díaz Barriga SL, Guisa CVM, et al. Historia Clínica Psiquiátrica Codificada para Adicciones, HCPCA. Psiquiatría 1998; 14(1): 13-25.

  10. Souza y MM. Nosología y terapéutica de los programas contra las adicciones. México: Dirección de Tratamiento. Centros de Integración Juvenil, A.C.; 2004.

  11. APA. Diagnostical and statistical manual of mental disorders. DSM-IV-TR. Washington; 2000.

  12. OMS. Organización Mundial de la Salud. Décima Revisión Internacional de la Clasificación de Enfermedades. Capítulo V. Desordenes mentales, conductuales y del desarrollo. Ginebra, Suiza: OMS; 1993.

  13. Ciraulo DA, Piechniczek-Buczek J, Nalan Iscan E. Outcome predictors in substance use disorders. Psychiatric Clinics of North America 2003; 26(2): 36-72.

  14. Souza y MM. Filosofía y políticas de los programas terapéuticos contra las adicciones. Dirección de Tratamiento. México: Centros de Integración Juvenil, A.C.; 2004.

  15. DeMet EM. Addictive behaviour: molecules to mankind; perspectives on the nature of addiction. N Engl J Med 1997; 336: 299.

  16. O’Connor PG, Schottenfeld RS. Medical progress: patients with alcohol problems. N Engl J Med 1998; 338: 592-602.

  17. Díaz P. Adolescent substance abuse: assessment in the office. Pediatric Clinics of North America 2002; 49(2): 1-23.

  18. Souza y MM. Apuntes de pareja. Memorias del Seminario de la Escuela de Orientación para Padres. Nuevos Enfoques. Dirección de Prevención y Bienestar Familiar del DIF-Estado de México; 2000.

  19. 19 Newcomb MD. Psychosocial predictors and consequences of drug use: a development perspective within a prospective study. J Addict Dis 1997; 16: 57-89.

  20. 20 O’Connor PG, Selwyn PA, Schottenfeld RS. Medical progress: medical care for injection-drug users with HIV infection. N Engl J Med 1994; 331: 450-9.

  21. Souza y MM, Martínez AJ, Martínez MJ, Mercado CG, Tagle OI. Craving, adicción etílica y terapéutica. Archivos de Neurociencias México 2000; 5(4): 201-4.

  22. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GEA. Comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000; 343: 1290-7.

  23. Cloninger CR, Bohman M, Sigvardsson S. Inheritance of alcohol abuse: cross-fostering analysis of adopted men. Arch Gen Psychiatry 1981; 38(8): 861-8.

  24. Koob GF, Sanna PP, Bloom FE. Neuroscience of addiction. Neuron 1998; 21: 467-76.

  25. Picciotto MR. Common aspects of the action of nicotine and other drugs of abuse. Drug Alcohol Depend 1998; 51: 165-72.

  26. Brauer LH, Behm FM, Westman EC, Patel P, Rose JE. Naltrexone blockade of nicotine effects in cigarette smokers. Psychopharmacology 1999; 143: 339-46.

  27. Hughes JR, Goldstein MG, Hurt RD, Shiffman S. Recent advances in the pharmacotherapy of smoking. JAMA 1999; 281: 72-6.

  28. Koob GF, Weiss F. Neuropharmacology of cocaine and ethanol dependence. In: Galanter M (Ed.). Recent developments in alcoholism. Vol. 10. N.Y.: Plenum Press; 1992. p. 201-33.

  29. Swift RM. Drug therapy: drug therapy for alcohol dependence. N Engl J Med 1999; 340: 1482-90.

  30. 30 Li TK. Pharmacogenetics of responses to alcohol and genes that influence alcohol drinking. J Stud Alcohol 2000; 61: 5-12.

  31. Cowen MS, Lawrence AJ. The role of opioid-dopamine interactions in the induction and maintenance of ethanol consumption. Prog Neuropsychopharmacol Biol Psychiatry 1999; 23: 1171-212.

  32. Repo E, Kuikka JT, Bergstron KA, Karhu J, Hiltunen J, Tiihonen J. Dopamine transporter and D2-receptor density in late-onset alcoholism. Psychopharmacology 1999; 147: 314-8.

  33. Volkow ND, Wang GJ, Fowler JS, Logan J, Hitzemann R. Decreases in dopamine receptors but not in dopamine transporters in alcoholics. Alcohol Clin Exp Res 1996; 20: 1594-8.

  34. Tupala E, Hall H, Sarkioja T, Rasanen P, Tiihonen J. Dopamine-transporter denisty in nucleus accumbens of type-1 alcoholics. Lancet 2000; 355: 380.

  35. Guardia J, Catafau AM, Battle F, Martin JC, Segura L, Gonzalvo B. Striatal dopaminergic D(2) receptor density measured by [(123)I] iodobenzamide SPECT in the prediction of treatment outcome of alcohol-dependent patients. Am J Psychiatry 2000; 157: 127-9.

  36. Gatch MB, Lal H. Pharmacological treatment of alcoholism. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22: 917-44.

  37. Volpicelli JR, Alterman AI, Hayasgida M, O’Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49: 876-80.

  38. O’Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. Arch Gen Psychiatry 1992; 49: 881-7.

  39. Freedman R. Psychiatric genetics and genomics. N Engl J Med 2003; 349: 411-2.

  40. Musto DF. Creating the American junkie: addiction research in the classic era of narcotic control. N Engl J Med 2003; 348: 2369-70.

  41. Johnson BA, Ait-Daoud N. Neuropharmalogical treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology 2000; 149: 327-44.

  42. Childress AR, Mozley PD, McElgin W, Fitzgerald J, Reivich M, O’Brien CP. Limbic activation during cue-induced cocaine craving. Am J Psychiatry 1999; 156: 11-8.

  43. Whitworth AB, Fisher F, Lesch OM, Nimmerrichter A. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996; 347: 1438-42.

  44. Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K, Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. 90-day placebo-controlled dose-finding study. Br J Psychiatry 1997; 171: 73-7.

  45. Poldrugo F. Acamprosate treatment in a long term community-based alcohol rehabilitation program. Addiction 1997; 92: 1537-46.

  46. Geerlings PJ, Ansoms C, van den Brink W. Acamprosate and prevention of relapse in alcoholics. Eur Addict Res 1997; 3: 129-37.

  47. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685-91.

  48. Riggs P, León SL, Mikulich S. An open trial of bupropion for ADHD in adolescents with substance abuse disorders and conduct disorders. J Am Acad Child Adolesc Psychiatry 1998; 37: 1271-8.

  49. Johnson BA, Ait-Daoud N, Prihoda TJ. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypothesis to preliminary clinical evidence. Alcohol Clin Exp Res 2000; 24: 737-42.

  50. Baxter LR, Schwartz JM, Phelps ME, Mazziotta JC. Localization of neurochemical effects of cocaine and other stimulants in the human brain. J Clin Psychiatry 1988; 49: 23-6.

  51. Little KY, Carroll FI, Butts JD. Striatal [125I]RTI-55 binding sites in cocaine abusing humans. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22: 455-66.

  52. Little KY, McLaughlin DP, Zhang L, McFinton PR, Dalack GW, Cook EH. Brain dopamine transporter messenger RNA and binding sites in cocaine users: a postmortem study. Arch Gen Psychiatry 1998; 55: 793-9.

  53. Klein M. Research issues related to development of medications for treatment of cocaine addiction. Ann N Y Acad Sci 1998; 844: 75-91.

  54. Tomkins DM, Sellers EM. Addiction and the brain: the role of neurotransmitters in the cause and treatment of drug dependence CMAJ 2001; 164(6): 817-21.

  55. Warner EA, Kosten TR, O’Connor PG. Pharmacotherapy for opioid and cocaine abuse. Med Clin North Am 1997; 81: 909-25.

  56. Effective medical treatment of opiate addiction. National consensus development panel on effective medical treatment of opiate addiction. JAMA 1998; 280: 1936-43.

  57. Gerra G, Marcato A, Caccavari R, Fontanesi B, Delsignore R. Clonidine and opiate receptor antagonists in the treatment of heroin addiction. J Subst Abuse Treat 1995; 12: 35-41.

  58. Parsian A, Cloninger CR. Serotonergic pathway genes and subtypes of alcoholism: association studies. Psychiatr Genet 2001; 11: 89-94.

  59. Meszaros K, Lenzinger E, Hornik K, Fureder T, Willinger U. The tridimensional personality questionnaire as a predictor of relapse in detoxified alcohol dependents. The European fluvoxamine in alcoholism study group. Alcohol Clin Exp Res 1999; 23: 483-6.

  60. Cloninger CR. Neurogenetic adaptive mechanisms in alcoholism. Science 1987; 236: 410-6.

  61. Babor TF, Hofmann M, DelBoca FK, Hesselbrock V, Meyer RE. Types of alcoholics, I. Evidence for an empirically derived typology based on indicators of vulnerability and severity. Arch Gen Psychiatry 1992; 49: 599-608.

  62. Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA 2000; 284: 963-71.

  63. Tagle OI, Mercado CG, Martínez AJ, Martínez MJ, Souza y MM. Por que profesionalizar la terapéutica de las adicciones. Psiquiatría 2000; 2a Época; 16(3): 110-6.

  64. Souza y MM. Adicciones, psicopatología y psicoterapia. Rev Mex Neuroci 2004; 5(1): 206-8.

  65. Millán S. El psicoanálisis contemporáneo. Simposio de la Federación Internacional de Sociedades Psicoanalíticas IFPS e Instituto Mexicano de Psicoanálisis, A.C. XVII Congreso Nacional de la Asociación Psiquiátrica Mexicana, A.C., y Simposio Regional de la Asociación Psiquiátrica de América Latina. Cancún, Q. Roo. 16-20 Nov. del 2001.

  66. Kaplan HI, Sadock BJ, Grebb JA. Synopsis of psychiatry. 7th Ed. Washington: William and Wilkins: 1994.

  67. Souza y MM. Enseñanza e investigación en adicciones en la ciudad de México. Psiquiatría 1998; 2a Época; 14(3): 100-6.

  68. Guisa CVM, Díaz Barriga SL, Souza y MM. A propósito de la relación entre adicciones y delincuencia. Psiquiatría 2003; 2a Época; 19(1): 14-27.

  69. Souza y MM. El papel de la mitología popular, la semántica y la iatrogenia en las adicciones. Rev Mex Neuroci 2001; 2(1): 25-7.

  70. Souza y MM. La deficiencia formativa del personal de salud y la terapéutica de las adicciones. Rev Mex Preven Readap Soc 2000; 8: 99-106.

  71. Kaufman E, McNul J. Recent advances at the comprehension and treatment of drug abuse and dependence. Hosp Comm Psychiat 1992; 43(3): 220-32.

  72. Kaufman E. Diagnosis and treatment of drug and alcohol abuse in women. Am J Obstet Gynecol 1996; 174(1): 21-7.

  73. Kosten TR. The pharmacotherapy of relapse prevention using anticonvulsants. Am J Addict Summer 1998; 7(3): 205-9.

  74. Kosten TR. Drug alcohol withdrawal management. N Eng J Med 2003; 348: 1786c-95.

  75. Olivares HM, Tagle OI, Mercado CG, Souza y MM. Psicodinamia y psicoterapia del paciente adicto. Psiquiatría 2003; 2a Época; 19(1): 28-38.

  76. Souza y MM. Acerca de la educación y el entrenamiento clínico en adicciones. Psiquiatría 2004.

  77. Souza y MM. Principios generales de psicoterapia: un lugar en la terapéutica por derecho propio. I Simposium de patología psiquiátrica del Gobierno del Estado de Tamaulipas. Secretaría Estatal de Salud. Universidad Autónoma del Estado de Tamaulipas y Hospital General de Ciudad Victoria, Tamps.; 1996.

  78. Volkow ND, Fowler JS, Wang GJ, Goldstein RZ. Role of dopamine, the frontal cortex and memory circuits in drug addiction: insight from imaging studies. Behav Pharmacol 2002; 15(8): 284-96.

  79. Goldstein RZ, Volkow ND. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 2002; 159(10): 1642-52.

  80. Volkow ND, Fowler JS, Wang GJ. Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies. Behav Pharmacol 2002; 13(5-6): 355-66.

  81. Willner P, Young A, Sanger D. New advances in the understanding and treatment of addiction. Behavioural Pharmacolgy 2002; 13(5-6): 323-5.

  82. Kyriacou DN, Anglin D, Taliaferro E, Stone S, Tubb T, Linden JA, Muelleman R, Barton E, Kraus JF. Risk factors for injury to women from domestic violence. N Engl J Med 1999; 341: 1892-8.

  83. De Moore GM, Robertson AR, Wintemute GJ. Firearms and suicide. N Engl J Med 2000; 342: 1528-9.

  84. Muñoz R. La personalidad y las personalidades. Conferencia magistral. Congreso Regional Vicepresidencia Noroeste “Trastornos de la personalidad y su comorbilidad”. Asociación Psiquiátrica Mexicana, A.C. San Carlos, Guaymas, Sonora. 3-6 de junio, 2004.

  85. Freedman R. Psychiatric genetics and genomics. N Engl J Med 2003; 349: 411-2.

  86. Westermeyer J. Addiction psychiatry: current diagnosis and treatment. N Engl J Med 1995; 333: 1158-9.

  87. Souza y MM. Una mirada reflexiva a la terapéutica de las adicciones. Dirección de Tratamiento. México: Centros de Integración Juvenil, A.C.; 2004.




2020     |     www.medigraphic.com